Eleftheria Hatzimichael: ASH 2026 Guidelines for Primary ITP What Is Changing
Eleftheria Hatzimichael, Special Secretary of the Board of Directors at Hellenic Society of Hematology, shared a post on LinkedIn:
“ASH 2026 Guidelines for Primary ITP — what is changing?
The new ASH focused update brings an important shift in the management of adults with primary ITP: moving beyond corticosteroids alone and beyond platelet count as the main therapeutic goal.
For initial therapy, rituximab plus corticosteroids or a thrombopoietic agent plus corticosteroids are now suggested over corticosteroids alone.
After failure of first-line corticosteroids, thrombopoietic agents receive a strong recommendation, while rituximab remains an important alternative.
Perhaps the most important message, however, is broader: treatment should focus on outcomes that matter to patients bleeding, fatigue, quality of life, treatment burden and sustained response off therapy, not simply achieving a higher platelet count.
A useful update for everyday hematology practice summarized in the infographic below.”
Stay updated with Hemostasis Today.
-
Aug 29, 2026, 16:03Marco De Giovanni: The Platelet – Serotonin Link Behind Severe COVID-19
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:53Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community
-
Aug 29, 2026, 15:49Ujjawal Agarwal: Alkem’s Fight Against Anemia in Rural Bihar
-
Aug 29, 2026, 15:44Christopher Cannon: Anticoagulation Shows Benefits Even in Low Risk Atrial Fibrillation Patients
-
Aug 29, 2026, 15:43Aniela Popescu: Heart Failure Care Enters a New Era With the 2026 ESC Guidelines